Fagron North America debuts the TrichoTest, a genetic test for alopecia that is performed on patients’ DNA.
TrichoTest is designed to analyze 13 genes and 48 genetic variations related to alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium. It is based on DNA microarray technology and utilizes a patented algorithm to provide a personalized treatment recommendation to medical practitioners from 175 million therapeutic alternatives.
In addition, TrichoTest analyzes prostaglandins metabolism, inflammation, androgenic effect, vasodilation and blood circulation, collagen synthesis, vitamins and minerals metabolism, and insulin-like growth factor metabolism, a media release from Fagron North America notes.
Alopecia is a progressive and multifactorial condition related to endogenous and exogenous factors. Often, endogenous factors are genetics and associated with gene expression. The most common type of hair loss, known as androgenetic alopecia, is hereditary. If left untreated, hair loss usually progresses over time.
The test results can help medical practitioners develop a personalized treatment plan for their patients, which may include compounded topical solutions, oral supplements, and prescription hair care products, according to the company.
TrichoTest is not approved by the US Food and Drug Administration and is not intended to diagnose, treat, cure or prevent disease, the company emphasizes in the release. Any recommendations given to the requesting medical practitioner are for informational purposes only, and no individual is required to use any products mentioned in a report.
[Source(s): Fagron North America, PR Newswire]